Crescent Biopharma, Inc. Total Assets
Crescent Biopharma, Inc. total assets. Based on the latest financial reports, Crescent Biopharma, Inc. (CBIO) holds total assets worth $182.76 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CBIO stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Crescent Biopharma, Inc. (2011–2025)
Total assets of Crescent Biopharma, Inc. from 2011 to 2025. This chart illustrates how Crescent Biopharma, Inc.'s total assets have evolved over time, based on quarterly financial data. See CBIO live share price for real-time trading data and today's change.
Crescent Biopharma, Inc. - Asset Composition Analysis
Crescent Biopharma, Inc. Total Assets Breakdown (December 2025)
Crescent Biopharma, Inc. total assets breakdown as of December 2025. Crescent Biopharma, Inc.'s total assets of $182.76 Million consist of 98.5% current assets and 1.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.7% |
| Accounts Receivable | $18.00 Million | 7.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.73 Million | 2.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Crescent Biopharma, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Crescent Biopharma, Inc. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crescent Biopharma, Inc.'s current assets represent 98.5% of total assets in 2025, an increase from 98.1% in 2011.
- Cash Position: Cash and equivalents constituted 88.7% of total assets in 2025, down from 97.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 7.5% of total assets.
Crescent Biopharma, Inc. Competitors by Total Assets
Key competitors of Crescent Biopharma, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Crescent Biopharma, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.66 | 9.21 | 10.78 |
| Quick Ratio | 9.66 | 9.21 | 10.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $160.47 Million | $137.48 Million | $94.47 Million |
Crescent Biopharma, Inc. - Advanced Valuation Insights
This section examines the relationship between Crescent Biopharma, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.31 |
| Latest Market Cap to Assets Ratio | 2.14 |
| Asset Growth Rate (YoY) | 574.7% |
| Total Assets | $240.29 Million |
| Market Capitalization | $513.33 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Crescent Biopharma, Inc.'s assets at a significant premium (2.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Crescent Biopharma, Inc.'s assets grew by 574.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Crescent Biopharma, Inc. (2011–2025)
The table below shows the annual total assets of Crescent Biopharma, Inc. from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $240.29 Million | +574.66% |
| 2024-12-31 | $35.62 Million | -21.40% |
| 2023-12-31 | $45.32 Million | -12.53% |
| 2022-12-31 | $51.81 Million | -45.08% |
| 2021-12-31 | $94.35 Million | -33.95% |
| 2020-12-31 | $142.83 Million | -14.97% |
| 2019-12-31 | $167.97 Million | -21.82% |
| 2018-12-31 | $214.84 Million | +67.08% |
| 2017-12-31 | $128.58 Million | +203.35% |
| 2016-12-31 | $42.39 Million | -12.53% |
| 2015-12-31 | $48.46 Million | -15.37% |
| 2014-12-31 | $57.26 Million | +983.83% |
| 2013-12-31 | $5.28 Million | -71.32% |
| 2012-12-31 | $18.42 Million | -36.28% |
| 2011-12-31 | $28.91 Million | -- |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more